A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, symptoms and biomarker response of subjects with
biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic
pancreatic neuroendocrine tumors (PNETs) or or Gastrointestinal Neuroendocrine tumors
(GI-NETs) with elevated biochemical markers who have relapsed during or after receiving prior
standard of care therapies, including octreotide, chemotherapy or targeted therapy.